These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 17605064)

  • 1. [Molecular pathogenesis of hepatocellular carcinoma: new therapeutic approaches and predictive pathology].
    Kern MA; Breuhahn K; Schuchmann M; Schirmacher P
    Pathologe; 2007 Jul; 28(4):261-8. PubMed ID: 17605064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hepatocellular carcinoma: novel molecular aspects for differential diagnosis and therapy].
    Kern MA; Schirmacher P
    Verh Dtsch Ges Pathol; 2006; 90():85-98. PubMed ID: 17867584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic silencing of miR-144/451a cluster contributes to HCC progression via paracrine HGF/MIF-mediated TAM remodeling.
    Zhao J; Li H; Zhao S; Wang E; Zhu J; Feng D; Zhu Y; Dou W; Fan Q; Hu J; Jia L; Liu L
    Mol Cancer; 2021 Mar; 20(1):46. PubMed ID: 33658044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma.
    Tavian D; De Petro G; Benetti A; Portolani N; Giulini SM; Barlati S
    Int J Cancer; 2000 Sep; 87(5):644-9. PubMed ID: 10925356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas.
    Kiss A; Wang NJ; Xie JP; Thorgeirsson SS
    Clin Cancer Res; 1997 Jul; 3(7):1059-66. PubMed ID: 9815784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
    Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma.
    Daveau M; Scotte M; François A; Coulouarn C; Ros G; Tallet Y; Hiron M; Hellot MF; Salier JP
    Mol Carcinog; 2003 Mar; 36(3):130-41. PubMed ID: 12619035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
    García-Vilas JA; Medina MÁ
    World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic upregulation of HGF and c-Met drives metastasis in hepatocellular carcinoma.
    Ogunwobi OO; Puszyk W; Dong HJ; Liu C
    PLoS One; 2013; 8(5):e63765. PubMed ID: 23723997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-MET and HGF mRNA expression in hepatocellular carcinoma: correlation with clinicopathological features and survival.
    Ang CS; Sun MY; Huitzil-Melendez DF; Chou JF; Capanu M; Jarnagin W; Fong Y; Dematteo RP; D'Angelica M; Allen P; Chen CT; O'Reilly EM; Weiser MR; Abou-Alfa GK
    Anticancer Res; 2013 Aug; 33(8):3241-5. PubMed ID: 23898085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma.
    Peng SY; Chou SP; Hsu HC
    J Hepatol; 1998 Aug; 29(2):281-9. PubMed ID: 9722210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of hepatocyte growth factor and its receptor c-met proto-oncogene in hepatocellular carcinoma.
    Ueki T; Fujimoto J; Suzuki T; Yamamoto H; Okamoto E
    Hepatology; 1997 Apr; 25(4):862-6. PubMed ID: 9096589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing pathology with changing drugs: tumors of the gastrointestinal tract.
    Cervera P; Fléjou JF
    Pathobiology; 2011; 78(2):76-89. PubMed ID: 21677471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deubiquitinating enzyme USP46 suppresses the progression of hepatocellular carcinoma by stabilizing MST1.
    Qiu Y; Huang D; Sheng Y; Huang J; Li N; Zhang S; Hong Z; Yin X; Yan J
    Exp Cell Res; 2021 Aug; 405(1):112646. PubMed ID: 34029571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC-regulated genes involved in liver cell dysplasia identified in a transgenic model of liver cancer.
    Hunecke D; Spanel R; Länger F; Nam SW; Borlak J
    J Pathol; 2012 Dec; 228(4):520-33. PubMed ID: 22653869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
    Liu Y; Tan J; Ou S; Chen J; Chen L
    Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of proproliferative genes and the ligand/receptor pair placental growth factor and vascular endothelial growth factor receptor 1 in hepatitis C cirrhosis.
    Huang XX; McCaughan GW; Shackel NA; Gorrell MD
    Liver Int; 2007 Sep; 27(7):960-8. PubMed ID: 17696935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular pathogenesis of human hepatocellular carcinoma.
    Thorgeirsson SS; Grisham JW
    Nat Genet; 2002 Aug; 31(4):339-46. PubMed ID: 12149612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2-p53 pathway in hepatocellular carcinoma.
    Meng X; Franklin DA; Dong J; Zhang Y
    Cancer Res; 2014 Dec; 74(24):7161-7. PubMed ID: 25477334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expressions of c-met and hepatocyte growth factor in chronic liver disease and hepatocellular carcinoma.
    Noguchi O; Enomoto N; Ikeda T; Kobayashi F; Marumo F; Sato C
    J Hepatol; 1996 Mar; 24(3):286-92. PubMed ID: 8778194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.